204 related articles for article (PubMed ID: 33088686)
1. Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors.
Ma L; Wang H; You Y; Ma C; Liu Y; Yang F; Zheng Y; Liu H
Acta Pharm Sin B; 2020 Sep; 10(9):1658-1668. PubMed ID: 33088686
[TBL] [Abstract][Full Text] [Related]
2. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
[TBL] [Abstract][Full Text] [Related]
3. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
[TBL] [Abstract][Full Text] [Related]
4. Natural products as LSD1 inhibitors for cancer therapy.
Fang Y; Yang C; Yu Z; Li X; Mu Q; Liao G; Yu B
Acta Pharm Sin B; 2020 Jun; 11(3):621-31. PubMed ID: 32837872
[TBL] [Abstract][Full Text] [Related]
5. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
[TBL] [Abstract][Full Text] [Related]
6. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
7. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).
Kanouni T; Severin C; Cho RW; Yuen NY; Xu J; Shi L; Lai C; Del Rosario JR; Stansfield RK; Lawton LN; Hosfield D; O'Connell S; Kreilein MM; Tavares-Greco P; Nie Z; Kaldor SW; Veal JM; Stafford JA; Chen YK
J Med Chem; 2020 Dec; 63(23):14522-14529. PubMed ID: 33034194
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors.
Wang S; Li ZR; Suo FZ; Yuan XH; Yu B; Liu HM
Eur J Med Chem; 2019 Apr; 167():388-401. PubMed ID: 30780087
[TBL] [Abstract][Full Text] [Related]
14. Discovery of [1,2,3]Triazolo[4,5-
Li ZH; Liu XQ; Geng PF; Suo FZ; Ma JL; Yu B; Zhao TQ; Zhou ZQ; Huang CX; Zheng YC; Liu HM
ACS Med Chem Lett; 2017 Apr; 8(4):384-389. PubMed ID: 28435523
[TBL] [Abstract][Full Text] [Related]
15. Probing the binding mode and unbinding mechanism of LSD1 inhibitors by combined computational methods.
Sun X; Ding L; Liu HM
Phys Chem Chem Phys; 2018 Dec; 20(47):29833-29846. PubMed ID: 30468219
[TBL] [Abstract][Full Text] [Related]
16. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
17. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM
Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950
[TBL] [Abstract][Full Text] [Related]
18. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
Noce B; Di Bello E; Fioravanti R; Mai A
Front Pharmacol; 2023; 14():1120911. PubMed ID: 36817147
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma.
Ma Y; Zheng Y; Ji Y; Wang X; Ye B
Future Med Chem; 2021 Mar; 13(6):533-542. PubMed ID: 33527838
[No Abstract] [Full Text] [Related]
20. A mechanism-based inactivator for histone demethylase LSD1.
Culhane JC; Szewczuk LM; Liu X; Da G; Marmorstein R; Cole PA
J Am Chem Soc; 2006 Apr; 128(14):4536-7. PubMed ID: 16594666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
